Latest Updates of Viva Biotech's Portfolio Companies
- Positive Phase 1 clinical trial data for AL01211 with 78% reduction in plasma glucosylceramide and 52% reduction in globotriaosylceramide.
- Basking Biosciences secured $55 million financing for BB-031, a reversible thrombolytic therapy for stroke.
- Technoderma Medicines received multi-million dollar funding for hair loss and dermatitis projects.
- Full-Life Technologies raised $63.3 million for radiopharmaceutical pipeline and manufacturing capabilities.
- Absci partnered with AstraZeneca for AI-designed antibody against an oncology target with potential total payment of $247 million.
- None.
Insights
The announcements made by Viva Biotech's portfolio companies indicate significant developments in their respective pipelines and financial strategies. AceLink Therapeutics' publication of Phase 1 clinical trial data for AL01211 marks a key step in the drug development process, transitioning from safety assessments in healthy volunteers to potentially more complex efficacy trials in patients. This can be a value inflection point for investors, as positive data can lead to increased investment and partnerships.
Basking Biosciences' $55 million financing round, led by ARCH Venture Partners, is a substantial capital injection that will enable the company to expedite the clinical development of BB-031. The involvement of a high-profile new chairman and reputable investors suggests strong market confidence in Basking's technology and strategy. This financing is expected to extend the company's runway and enhance its valuation, potentially affecting the stock performance of Viva BioInnovator and its stakeholders.
Technoderma Medicines' successful completion of a Pre-B round and Phase 2a clinical trial for TDM-105795, as well as a Phase I trial for TDM-180935, signifies progress in its clinical pipeline. The results from these trials could catalyze further investment and partnerships, important for the company's long-term growth and investor returns.
Full-Life Technologies' Series B financing and the establishment of a GMP manufacturing facility in Belgium represent strategic moves to scale up production capabilities and advance their radiopharmaceutical pipeline. This could lead to increased market share and revenue potential in the growing field of radiotherapeutics, impacting the company's financial outlook.
The collaboration between Absci and AstraZeneca, with a deal potentially worth up to $247 million, underscores the significant revenue and growth potential through partnerships in the biopharmaceutical industry. It highlights the value that AI-driven platforms can bring to drug discovery, potentially reducing time and costs associated with R&D, which can be a strong selling point for investors.
AceLink Therapeutics' AL01211, a glucosylceramide synthase inhibitor, shows promise for the treatment of lysosomal storage disorders such as Fabry and Gaucher diseases. The reported reduction in plasma glucosylceramide and globotriaosylceramide is a positive indication of the drug's mechanism of action. These results may facilitate the entry into later-stage clinical trials, which are critical for regulatory approval and commercialization. The success of these trials will be pivotal in determining the drug's market potential and patient impact.
Basking Biosciences' BB-031 targets von Willebrand Factor to treat stroke, an area with a high unmet medical need. As a reversible thrombolytic, it could offer a significant advantage over existing treatments by potentially reducing the risk of bleeding complications. Rapid progress through clinical development could position the company as a leader in acute stroke management, with significant implications for patient outcomes and healthcare costs.
Technoderma Medicines' focus on dermatological conditions addresses another area with substantial patient populations. The successful completion of early-phase trials for androgenetic alopecia and atopic dermatitis treatments suggests potential for addressing market gaps. The progression of these drugs through the clinical pipeline will be closely monitored for efficacy and safety, which will influence their market adoption and competitive positioning.
Full-Life Technologies' radiopharmaceutical pipeline and manufacturing capabilities are particularly noteworthy as the field of nuclear medicine is rapidly evolving. The investment in GMP facilities aligns with the increasing demand for high-quality radiopharmaceuticals, which are used in both diagnostic imaging and targeted therapy for cancer and other diseases. The company's UniRDCTM discovery platform may lead to a diversified pipeline, offering multiple avenues for revenue and growth.
The biopharmaceutical industry is characterized by high R&D costs and long development timelines. The financial and clinical milestones achieved by Viva Biotech's portfolio companies are indicative of their potential to capture market share in their respective therapeutic areas. The success of AceLink Therapeutics, Basking Biosciences, Technoderma Medicines and Full-Life Technologies in advancing their pipelines and securing funding reflects a positive trend in investor sentiment towards innovative biotech companies.
The strategic positioning of Full-Life Technologies in Belgium, a key logistical hub, could provide competitive advantages in the European market, enhancing its ability to meet global demand. The establishment of new facilities and advancement of the radiopharmaceutical pipeline may attract attention from potential partners and investors interested in the radiopharmaceutical space.
Moreover, the collaboration between Absci and AstraZeneca represents a significant validation of AI in drug discovery. As this technology continues to gain traction, it could reshape the competitive landscape of the oncology market, with implications for investment strategies and market dynamics. The potential financial impact of such collaborations, including milestone payments, has the power to significantly alter the valuation of companies involved.
AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers
In the published Phase 1 study, AL01211 was evaluated with a single ascending dose arm and a multiple ascending dose arm to determine the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects in healthy volunteers. Overall, AL01211 was generally safe and well-tolerated with no serious adverse events. At a 30 mg dose level, plasma glucosylceramide and globotriaosylceramide were reduced from baseline levels by
Basking Biosciences Announces Close of
Basking will utilize the proceeds to accelerate clinical development of BB-031, a first-in-class, reversible RNA aptamer targeting von Willebrand Factor (vWF), engineered for rapid onset and short duration of effect.
Technoderma Medicines Secures Multi-Million Dollar Pre-B Round Financing , and Its Globally First-in-Class New Drug TDM-105795 for Treating Androgenetic Alopecia Completes Phase 2a Clinical Trial Successfully and Completes Phase I Dose Escalation Clinical Trial of TDM-180935 for Eczema/Dermatitis Indication
According to VBDATA.CN on January 15th, Technoderma Medicines, Inc. ("Technoderma Medicines"), a clinical-stage company focused on new drug development for skin diseases that was incubated and invested by Viva BioInnovator, announced that it has recently completed a Pre-B round financing of tens of millions of RMB. This round of financing raised will be used for subsequent clinical development of the hair loss project and Phase 2 clinical trials (
On Dec. 4th, 2023, Technoderma Medicines announced that it has completed a Phase I clinical trial (NCT05525468) of TDM-180935 topical ointment for the treatment of atopic dermatitis/eczema. The results all met expectations.
Full-Life Technologies Announces USD
On Dec. 8th, 2023, Full-Life aslo announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux,
VivaVision Receives Funding from the "Enterprise Support Scheme" of
Vivavision's subsidiary, which is a company focused on differentiated and globally novel ophthalmic innovative drugs and was incubated and invested in by Viva BioInnovator (VBI), recently announced that its innovative retinal drug VVN481 has successfully obtained funding from
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
About AceLink Therapeutics, Inc.
Founded in 2018, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address genetic diseases with high unmet needs. The company's initial focus is to develop novel therapeutics for Fabry disease. For more information, please visit www.acelinktherapeutics.com.
About Basking Biosciences
Basking Biosciences, a clinical-stage biopharmaceutical company, was founded to solve the biggest need in acute thrombosis – for a rapid-onset, short-acting thrombolytic drug capable of reopening blocked arteries, and whose activity can be quickly reversed in the event of a bleeding complication. Leveraging RNA aptamer technology, our lead drug candidate, BB-031, targets von Willebrand Factor (vWF), an important structural component of blood clots and driver of the clotting process, and is designed to be safer, more effective, and able to greatly expand the population receiving acute revascularization therapy.
For more information, visit BaskingBiosciences.com.
About Technoderma Medicines
Technoderma Medicines, Inc. is a privately held clinical stage biopharmaceutical company. The Company was originally located in Jiaxing Xiuzhou Biomedicine Guoqian Park,
About Full-Life Technologies
Full-Life Technologies Limited ("Full-Life") is a fully integrated global radiotherapeutics company with operations in
About VivaVision Biotech
VivaVision is a clinical stage pharmaceutical company focused on best-in-class and first-in-class therapies for ocular diseases. VivaVision's current pipeline includes VVN001 for treating dry eye syndrome, VVN539 for the treatment for Glaucoma or Ocular Hypertension, and VVN461 for the treatment of non-infectious ocular inflammation of Uveitis. VivaVision is also engaged in discovery and development of novel therapies for the treatment of other anterior and posterior eye diseases. For more info, visit www.vivavisionbio.com.
About Absci
Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, Absci can screen billions of cells per week, allowing it to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci's vision is to deliver breakthrough therapeutics at the click of a button, for everyone. Absci's headquarters is in
View original content:https://www.prnewswire.com/news-releases/latest-updates-of-viva-biotechs-portfolio-companies-302081340.html
SOURCE Viva Biotech Holdings
FAQ
What positive results were seen in the Phase 1 clinical trial data for AL01211?
How much financing did Basking Biosciences secure for stroke therapy development?
What projects did Technoderma Medicines receive multi-million dollar financing for?
How much funding did Full-Life Technologies raise for their radiopharmaceutical pipeline?
Who did Absci partner with for an AI-driven oncology candidate?
